People with Huntington’s disease have greater variations in disease symptoms and physical function between days than within each day, according to a study based on patient reports and objective data collected with a wrist-worn device in the U.S. The findings suggest “it may be sufficient and reliable to evaluate…
Wave Life Sciences is making plans to launch a potentially pivotal Phase 2/3 clinical trial in the U.S. to test its therapy candidate WVE-003 in people with Huntington’s disease. Pivotal trials are those whose data, if positive, are meant to be used to support applications seeking a treatment’s…
The European Medicines Agency (EMA) has agreed to review Prilenia Therapeutics’ application seeking approval of pridopidine, an oral therapy candidate for adults with Huntington’s disease, the company announced. The regulatory application is based on safety and efficacy data from pridopidine’s clinical development program, which showed the therapy…
People with Huntington’s disease have significantly higher levels of the proinflammatory molecule interleukin-6 (IL-6) and the anti-inflammatory molecule IL-10 in their blood relative to healthy people, according to a review study. The IL-6 difference was true for both pre-manifest patients — those carrying Huntington’s-causing mutations, but not yet having…
Nonprofits around the world are hoping to “turn up the global volume” for Huntington’s Disease Awareness Month, an annual event in May to call attention to the disease, estimated to affect up to 7 per 100,000 people globally. In the U.S., about 41,000 Americans are affected by the disease,…
Get regular updates to your inbox.